Besides, clinically used therapeutic agents that are used to control excessive inflammation by inhibiting TLR4 signaling may be developed as obesity-associated CRC therapeutics, these include TAK-242, Candesartan, Valsartan, Fluvastatin, Simvastatin and Atorvastatin [48]. This evidence concerns the gene TLR4 and obesity due to melanocortin 4 receptor deficiency.